RxDoctor Payments Data

Alexandriah Alas, MD

Obstetrics & Gynecology · Pleasanton, CANPI 1003047515

Payments from drug & device makers

$5,295in general payments, 2019–2025

Across 61 payments — averaging $86.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Coloplast$1K
  • Boston Scientific$918
  • Axonics, Inc.$304
  • Biofire Diagnostics, LLC$300
  • Astellas Pharma US Inc$152
  • plus $314 from 7 others
$551in research payments, 2019–2025

Across 1 payment — averaging $551.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$551

What the payments were for

  • Speaking & faculty fees$3006%
  • Grants$3947%
  • Travel & lodging$74614%
  • Food & beverage$3,52767%
  • Education$3266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,295 in reported general payments places this provider in the 90th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$95,794
Medicare patients
180
Services billed
2,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron135$76,878
GemtesaVibegron56$45,730
Estradiol185$10,877
PremarinEstrogens, Conjugated12$3,636
Tolterodine Tartrate ErTolterodine Tartrate46$3,065
Methenamine Hippurate51$3,030
Trospium Chloride41$2,703
Trimethoprim54$2,526
Solifenacin Succinate52$1,346
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst78$959
Gabapentin36$791
NitrofurantoinNitrofurantoin Macrocrystal12$418
Cephalexin27$398
Duloxetine Hcl12$282
Oxybutynin Chloride ErOxybutynin Chloride17$173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$152$76,878135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Pleasanton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →